Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer

Exclusion Criteria

• •13.Patients must be available for treatment and follow up. Patients registered on this trial must be treated and followed at the participating center.
• •1.Pregnant or lactating women or women of childbearing potential not using adequate contraception.
• •2.Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin or other cancer curatively treated by surgery and with no evidence of disease for at least 5 years. Any prior treatment with radiotherapy or chemotherapy is an exclusion criterion.
• •3.Symptomatic peripheral neuropathy ³ grade 2 by NCIC-CTG criteria.
• •4.Symptomatic altered hearing \> grade 2 by NCIC-CTG criteria.
• •5.Other serious illnesses or medical conditions including but no limited to: Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry; History of significant neurologic or psychiatric disorders including dementia or seizures; Active uncontrolled infection; Active peptic ulcer; Hypercalcemia; Chronic obstructive pulmonary disease requiring hospitalization during the year preceding study entry.
• •6.Patients requiring intravenous alimentation.
• •7.Patients who experienced a weight loss of more than 20% of their body weight in the 3 months preceding study entry.
• •8.Concurrent treatment with any other anticancer therapy
• •9.Participation in an investigational trial within 30 days of study entry.